VIRI stock icon

Virios Therapeutics


About: Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Employees: 4

Funds holding %
of 6,689 funds
Analysts bullish %
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0% more funds holding

Funds holding: 20 [Q4 2023] → 20 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0.95% less ownership

Funds ownership: 4.47% [Q4 2023] → 3.52% (-0.95%) [Q1 2024]

34% less capital invested

Capital invested by funds: $493K [Q4 2023] → $325K (-$169K) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for VIRI.

Financial journalist opinion

Based on 4 articles about VIRI published over the past 30 days